"Diabetes - PubMed Health." PubMed Health. Ed. David Zieve and David R. Eltz. U.S. National Library of Medicine, 31 Aug. 2011. Web. 14 Nov. 2011. <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002194/>.…
Phase Two: If Merck decides to advance into Phase Two there presents a multitude of opportunities. The first decision involves treating just obesity at 10% likelihood. A 10% chance also exists of the drug treating only high cholesterol. There also is a possibility of the drug effectively addressing both conditions at 30%. The chance of the drug not treating any of the maladies is 50%. The cost of completing Phase Two is $40 million. For each condition that is addressed, the decision remains whether to seek out FDA approval. The program suggests if Phase Two is successful, the company has two feasible options, to produce a drug for just obesity or attain a drug that combats both obesity and…
Phase III – Performance of drug administered as intended once on market. Compared with other drugs currently on market for same illnesses.…
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.…
This year, about 580,350 US residents are expected to die of cancer – that’s nearly 1,600 people a day. Cancer is the second most common cause of death in the United States, exceeded only by heart disease. Cancer accounts for nearly 1 out of every 4 deaths in the United States. Drug prices are becoming a developing issue for every disease, especially for people who are uninsured. But the cost of cancer has shown an alarming increase and is steadily growing. As a list of more advanced biotech drugs become available the cost for treatment rounds costing $100,000, or even more, are no longer a rarity. With each new drug means more research which in turn means more money. Patients’ living longer is great news but also means they need treatment for longer periods which also increases cost. Prices reflect manufacturers’ years of research and development investment. Also, many drug companies donate a certain amount of medication to prescription-assistance programs that provide them for free to patients who otherwise couldn’t pay. This is a great program but is also extremely costly and directly contributes to the cost.…
Figure SEQ Figure \* ARABIC 5 Analysis of Price Sensitivities by Disease and Product Characteristics. These can be used to design endpoints in clinical trials…
Langreth, R. (2014, May). Big pharma 's favorite prescription: higher prices. , (), . Retrieved from…
As practitioners, the question remains: how do we help patients with type 1 diabetes manage glycaemia while overcoming barriers? In this article, the Global Partnership for Effective Diabetes Management provides practical recommendations to…
A call to action involving DTCA and regulated profits needs to combine all parties of, manufacturers, patients, providers, government, and public and private health plans. Americans need to become more educated and demand for change from people in higher power positions. Asking your primary care doctor is a great starting place to know what you're paying for. Some may argue that physicians are not reliable enough to speak cost because insurance policies differ, and although this is true doctors should know the difference between generic and new on-the-market medication. Doctors should generally not prescribe medication that their patients cannot afford and try to find alternatives. With many similar drugs, there sure has to be some alternatives…
SGLT2 is a protein in the kidney that facilitates glucose reabsorption. SGLT2 is located in the proximal tubule of the kidneys. It has low-affinity but is a high capacity glucose transporter. It accounts for 90% of glucose reabsorption in kidneys. Inhibition of SGLT2 causes reduced blood glucose due to increased renal glucose excretion. The mechanism of action of this new class of drugs also offers further glucose control by promoting increased activity of insulin, glucose uptake in the muscle cells, decreased gluconeogenesis and improved first phase insulin release from the beta…
There will always be a market for new drugs, e.g. Aging population therefore there is a shift in the drugs needed…
Introduction AstraZeneca PLC (AstraZeneca, AZN:NYSE, AZN:LSE) is one of the largest pharmaceutical companies in the world. It was formed in 1999 from the merger of Sweden’s Astra AB and UK’s Zeneca Group plc. Core Activities AstraZeneca is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. One of the key benefits of the merger between Astra and Zeneca is seen as their portfolio of new products in development: AstraZeneca call this their 'product pipeline'. – Cardiovascular product pipeline includes Saxagliptin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca's Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune. Dapagliflozin,…
Krein, S. L., et al. (2006). "Economics of Diabetes Mellitus." Nursing Clinics of North America…
Diabetes is a disease that afflicts millions of people worldwide each and every year. For many, diabetes has been with them for their entire lives, others however develop diabetes as they grow older. According to the World Health Organization, (WHO, 2011) 346 million people worldwide have diabetes. Approximately 3.4 million people died from consequences of high blood sugar in 2004 of which more than 80% of diabetes occur in low- and middle-income countries. It was also projected that the number of deaths as a result of diabetes will double between 2005 and 2030. Currently, diabetes imposes a large economic burden on the national healthcare system. Healthcare expenditures on diabetes account for 11.6% of the total healthcare expenditure in the world in 2010.…
National Institute of Health and Clinical Excellence (NICE) 2009 The Management of Type 2 Diabetes…